Arthrex prevails in patent dispute over wrist fracture device
30-03-2021
Fed Circ grants Arthrex remand, rejects Iancu conflict
10-09-2020
Photobyphm / Shutterstock.com
The US Court of Appeals for the Federal Circuit has thrown out Sanofi’s request to apply the recent Arthrex ruling on the constitutionality of the Patent Trial and Appeal Board (PTAB) to more cases.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, Arthrex, Sanofi, Mylan Pharmaceuticals, Patent Trial and Appeal Board, insulin
